OPKO HEALTH, INC.
No SEC Form 4 filings for $OPK in the last 30 days.
See all $OPK insider activity →OPKO Health reported Q2 2026 revenue of $163.58M, up from $156.81M, and a reduced net loss of $8.42M versus $148.44M a year earlier, though it remained unprofitable. The company also reiterated 2026 revenue guidance of $560M to $585M, shaping expectations for cost control and progress toward break-even.
Zacks upgraded OPKO Health (OPK) to a Zacks Rank #2 (Buy), citing rising earnings estimates. The Zacks Consensus Estimate increased 11.6% over the past three months. For FY ending Dec 2026, OPK is expected to earn -$0.26 EPS, unchanged year over year, according to Zacks.
Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
Over the past 7 days, alphai's AI scored 1 news story mentioning OPK (OPKO HEALTH, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OPK coverage spans earnings, financial news and market movers.
Lower Q2 loss and reiterated 2026 revenue range may support a modest bull-case reset, but the article flags ongoing unprofitability and funding risk.
The article frames the upgrade as driven by improving earnings estimate revisions, implying near-term upside bias from incremental estimate momentum.
The stock reaction suggests investors focused on Q2 and pipeline progress, but the guidance reset may cap upside.
The stock move is tied to a fresh earnings beat plus an upward guidance revision, with diagnostics and pharma mix changes supporting the narrative.
The quarter’s loss narrowing and diagnostics operating income shift can drive near-term momentum, but consolidated profitability durability remains uncertain.
alphai scores every news story that mentions OPK with an AI model for sentiment and relevance, and aggregates insider trades from OPKO HEALTH, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
OPKO Health reported Q2 2026 revenue of $163.58M, up from $156.81M, and a reduced net loss of $8.42M versus $148.44M a year earlier, though it remained unprofitable. The company also reiterated 2026 revenue guidance of $560M to $585M, shaping expectations for cost control and progress toward break-even.
5 min readZacks upgraded OPKO Health (OPK) to a Zacks Rank #2 (Buy), citing rising earnings estimates. The Zacks Consensus Estimate increased 11.6% over the past three months. For FY ending Dec 2026, OPK is expected to earn -$0.26 EPS, unchanged year over year, according to Zacks.
5 min readBiotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readOpko Health shares rose about 33% Tuesday after the company reported Q2 results. Revenue increased 4% to $163.5M and the net loss narrowed to $8.4M, or $0.01 per share. Opko also raised 2026 revenue guidance to $560M-$585M, above prior guidance and analyst estimates.
4 min readSimply Wall St reports OPKO Health (OPK) shares rose about 33% to around $1.65 after Q2 2026 results showed net loss narrowing to $8.4 million from $148.4 million on revenue of $163.6 million. Operating loss fell to about $7.0 million. The article cites diagnostics profit and ModeX pipeline enrollment progress, with cash above $300 million.
4 min readOPKO Health (NASDAQ: OPK) shares hit a new 52-week high after second-quarter 2026 news. The stock rose to about $1.65 (+33%) on July 28. OPKO reported Q2 revenue of $163.5M and net loss of $8.4M. Highlights included ModeX and OPK-88006 Phase 1 progress and an amended Nicoya deal.
4 min readMidday U.S. stocks were mostly higher. Boeing shares rose about 5% after the company reported Q2 2026 results: an adjusted loss of 76 cents per share, wider than the 30-cent estimate, and revenue up 8% to $24.56B versus $24.245B expected. Crude oil fell 5.4% to $78.17 and gold declined.
4 min readOPKO Health (OPK) reported Q2 2026 results: a loss of $0.01 per share, narrower than a year-ago loss of $0.19, and better than the Zacks Consensus estimate of a $0.08 loss. Revenues rose 4.3% to $163.5 million, beating estimates. Management raised FY26 revenue guidance to $560-$585 million. OPK shares were up 11.3% premarket.
6 min readOPKO Health (OPK) reported Q2 2026 revenue of $163.6 million versus $156.8 million a year earlier, with net loss of $8.4 million ($0.01/share). Diagnostics revenue was $74.5 million, including $6.2 million from 4Kscore. Pharmaceutical revenue rose to $89.0 million. OPK said Q3 2026 revenue should be $141–$142 million and full-year 2026 guidance is $560–$585 million.
4 min readOPKO HEALTH, INC. (OPK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 opk-ex99_1.htm EX-99.1 EX-99.1 OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results Conference Call to Begin Today at 4:30 p.m. ET MIAMI, July 27, 2026 – OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused o
6 min read
